• Use of the TheraBionic P1

    The TheraBionic P1 medical device is indicated for the systemic treatment of advanced hepatocellular carcinoma with or without metastases. It emits low levels of radiofrequency electromagnetic fields, which block the growth of tumor cells and do not affect the growth of normal cells.

    Learn more about the TheraBionic P1 medical de

  • About us

    The vision of TheraBionic’s founders is to further expand their findings using this technology both for diagnosis and treatment of several forms of cancer.

    Find out more about us!

  • What is hepatocellular carcinoma?

    Hepatocellular carcinoma (HCC) is the most common type of liver cancer accounting for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months. Infections such as chronic hepatitis B and/or hepatitis C are the main causes of HCC worldwide. Hepatitis B vaccination reduces the risk for HCC. Other causes include alcohol consumption and food containing aflatoxin B1.

    Learn more about HCC.

Hepatocellular carcinoma is a common disease

Cancer is the second most common cause of death worldwide and liver cancer is the second most common cause of cancer death. It accounted for 788,000 deaths in 2015 according to the World Health Organization: http://www.who.int/news-room/fact-sheets/detail/cancer. Hepatocellular carcinoma (HCC) is the most common type of liver cancer accounting for approximately 90% of all liver cancers, with average survival rates between 6 and 20 months.

Treatment with the TheraBionic P1 medical device

Until recently, only symptomatic treatment was advised for patients who have failed or are intolerant to first line and second line therapies for advanced hepatocellular carcinoma. As of 2018, a new treatment option is available for patients in the 28 countries of the European Economic Authority as well as in Iceland, Norway, Sweden and Switzerland.

The TheraBionic P1 device has received European regulatory approval as a breakthrough medical product for unmet medical needs for the treatment of patients with advanced hepatocellular carcinoma who have either failed or are intolerant to first line and second line therapies.

Comparison with the results from randomized studies conducted in patients with advanced hepatocellular carcinoma

This report describes a methodologically sound assessment of the therapeutic efficacy of the TheraBionic (TB) device by way of a statistical analysis of several studies. In this report the results of a single arm TheraBionic study are compared with control groups and treatment groups from two other studies. We examine three outcomes:

  1. Progression Free Survival
  2. Response Rate
  3. Overall Survival Among Patients who are not Child Pugh Class B

If you would like further information, please contact us.

The TheraBionic P1 medical device can only be obtained by prescription from a licensed physician.
 

About us

Boris Pasche and Alexandre Barbault, coinventors of the TheraBionic technology and cofounders of TheraBionic Inc., formerly TheraBionic LLC, and TheraBionic GmbH had one goal in mind since the beginning of their research: developing better and safer therapies for cancer.